Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in acute and critical care, recently announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes.
The purpose of the study was to test the performance of the company’s new, improved one-piece, cost-effective and easy-to-use biosensor. Echo Therapeutics’ non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and is designed to provide diabetic patients with an affordable and easy-to-use, needle-free continuous glucose monitoring device. The study tested roughly 900 Symphony tCGM glucose readings paired with reference blood glucose measurements and the MARD for the study was 12.89 percent. There were no adverse events reported from the Prelude skin permeation or the Symphony tCGM biosensor.
Patrick Mooney, M.D., chairman and chief executive officer of Echo Therapeutics, stated, “This study represents another major step forward in our Symphony development program. We believe that we have successfully developed a new cost-effective, one-piece biosensor and, with this study, we have demonstrated improvement in the accuracy of our Symphony system glucose readings.” Mr. Mooney continued, “Data from this study demonstrates that Symphony, using the new, improved, cost-effective biosensor, is safe, accurate and reliable at monitoring glucose levels. We look forward to continued progress with our Symphony development program throughout this year and next as we move toward our goal of making Symphony available to patients.”